Tirzepatide dramatically improves metabolic control in patient with acquired partial lipodystrophy post-HSCT

Acquired lipodystrophy is a rare disorder characterized by adipose tissue loss or dysfunction, frequently leading to severe insulin resistance and metabolic complications like diabetes mellitus and fatty liver disease. These complications are occasionally reported after hematopoietic stem cell transplantation (HSCT), but optimal treatment strategies remain poorly defined. Current standard-of-care often involves high-dose insulin and GLP-1 receptor agonists, which can be insufficient. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, offers a novel mechanism to address these complex metabolic derangements.

This case report details a 37-year-old woman who developed acquired partial lipodystrophy, diabetes mellitus, and fatty liver disease following allogeneic HSCT at 12 years of age. Her conditioning regimen included total body irradiation (TBI), high-dose cytarabine, and melphalan. Despite high-dose insulin therapy and sequential treatment with several GLP-1 receptor agonists, her glycemic control remained inadequate. Clinicians initiated tirzepatide therapy, with the primary endpoint being improvement in glycemic control and metabolic parameters. No specific dose or frequency for tirzepatide was detailed in the abstract.

Following the initiation of tirzepatide, the patient experienced a dramatic improvement in glycemic control, leading to the complete discontinuation of insulin therapy. This was particularly significant given her history of severe insulin resistance and prior failure of high-dose insulin and other GLP-1 receptor agonists. Body weight decreased modestly, and hepatic steatosis also improved. The abstract highlights a specific biomarker change:

The high-molecular-weight (HMW)/total adiponectin ratio after treatment was elevated (64.0%), suggesting a possible improvement in adipocyte secretory function. This finding points to a potential mechanism by which tirzepatide may be exerting its beneficial effects beyond simple glycemic control, possibly by improving fat cell function or reducing ectopic lipid accumulation.